Drug intelligence / Profile preview

carboplatin + docetaxel + melphalan

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Small Molecules
Administration: Intravenous

Overview

A high-dose chemotherapy regimen combining carboplatin (a platinum agent), docetaxel (a taxane), and melphalan (an alkylating agent). This combination is administered with autologous hematopoietic progenitor cell support (stem cell transplantation) for treatment of advanced refractory malignancies. In clinical studies, it has shown high response rates (95% with 47% complete responses) in heavily pretreated patients with various cancers including breast cancer, lymphomas, germ cell tumors, and ovarian cancer.

Targets

TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on carboplatin + docetaxel + melphalan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + docetaxel + melphalan.

Explore the full profile